SEPTInvestingStart Free

JANX 10-Q: SEC filing

Janux Therapeutics

Filed with the SEC on · accession 0001193125-26-449918

JANX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Janux Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results including cash position, R&D and G&A expenses, and collaboration agreements with Merck and BMS.

For details, click here →How to read a 10-Q →

Key details

FilerJanux Therapeutics, Inc.
Collaboration partnerMerck
Collaboration partnerBristol Myers Squibb
Cell line license agreement counterpartyWuXi Biologics
UnderwriterBofA Securities, Inc.

✦ Ask GOAX AI about this filing — what it means for JANX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for JANX?

Click here

Frequently asked questions

What did JANX file with the SEC on Nov 5, 2026?

JANX filed a 10-Q (SEC filing). Janux Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results including cash position, R&D and G&A expenses, and collaboration agreements with Merck and BMS.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other JANX SEC filings

Get alerts when JANX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
JANX overviewJANX analysisJANX newsLatest SEC filings